Daré Bioscience Launches Telehealth Access for First Evidence-Based Female Arousal Cream
Event summary
- Daré Bioscience has launched telehealth consultations for DARE to PLAY™ Sildenafil Cream, a non-hormonal topical arousal cream for women, available nationwide via the DARE Health Hub.
- The cream is the first evidence-based sildenafil formulation specifically designed for female sexual arousal, supported by clinical trials and peer-reviewed research.
- Prescriptions will be fulfilled through a 503B Outsourcing Facility, with a pre-fulfillment period allowing women to secure prescriptions before product dispensing begins.
- The company is pursuing a dual-path strategy, seeking FDA approval while making the product available as a compounded drug.
The big picture
Daré Bioscience's launch of telehealth access for DARE to PLAY™ Sildenafil Cream marks a strategic move to address a significant gap in women’s sexual health, where no FDA-approved therapeutics currently exist. The company’s dual-path approach—pursuing FDA approval while offering early access through a 503B facility—reflects broader industry trends in accelerating patient access to innovative treatments. The market opportunity is substantial, with an estimated 20 million women in the U.S. experiencing challenges related to genital arousal.
What we're watching
- Market Adoption
- Whether DARE to PLAY™ can gain significant market share in the underserved female sexual health space, given the lack of FDA-approved alternatives.
- Regulatory Pathway
- The pace at which Daré Bioscience advances toward FDA approval for its sildenafil cream formulation, balancing early patient access with regulatory compliance.
- Competitive Dynamics
- How existing products relying on marketing and consumer reviews respond to the introduction of an evidence-backed topical sildenafil cream.
Related topics